Loss of tubedown expression as a contributing factor in the development of age-related retinopathy

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 10, 2010, Pages 5267-5277

  Gendron, Robert L ^a   Laver, Nora V ^b   Good, William V ^c   Grossniklaus, Hans E ^d   Miskiewicz, Ewa ^a   Whelan, Maria A ^a   Walker, Jacqueline ^a   Paradis, Hélène ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b NEW ENGLAND EYE CENTER   (United States)

^c SMITH KETTLEWELL EYE RESEARCH INSTITUTE   (United States)

^d EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BETA GALACTOSIDASE; TUBEDOWN; UNCLASSIFIED DRUG; NARG1 PROTEIN, HUMAN; NARG1 PROTEIN, MOUSE; NERVE PROTEIN;

AGE RELATED NEOVASCULAR RETINOPATHY; AGED; AGING; ANIMAL TISSUE; ARTICLE; BRUCH MEMBRANE; CHOROID CAPILLARY LAYER; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; WESTERN BLOTTING; ADULT; ANIMAL; BASEMENT MEMBRANE; CHILD; CHOROID; ENZYME IMMUNOASSAY; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; RETINA; RETINA MACULA DEGENERATION; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ACETYLTRANSFERASES; ADULT; AGED; AGED, 80 AND OVER; AGING; ANIMALS; BASEMENT MEMBRANE; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CHOROID; HUMANS; IMMUNOENZYME TECHNIQUES; MACULAR DEGENERATION; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; RETINA; RETINAL PIGMENT EPITHELIUM;

EID: 77958119717     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4527     Document Type: Article

References (62)

1. Ambati J, Ambati K, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293.
2. Ferris FL III, Tielsch JM. Blindness and visual impairment: a public health issue for the future as well as today. Arch Ophthalmol. 2004;122:451-452.
3. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253-262.
4. Bonnel S, Mohand-Said S, Sahel JA. The aging of the retina. Exp Gerontol. 2003;38:825-831.
5. Lotery A, Trump D. Progress in defining the molecular biology of age related macular degeneration. Hum Genet. 2007;122:219-236.
6. Edwards AO, Malek G. Molecular genetics of AMD and current animal models. Angiogenesis. 2007;10:119-132.
7. Campochiaro PA. Molecular targets for retinal vascular diseases. J Cell Physiol. 2007;210:575-581.
8. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis: complex partnerships. Cell Mol Life Sci. 2006;63:601-615.
9. Gendron RL, Adams LC, Paradis H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. Dev Dyn. 2000;218:300-315.
10. Gendron RL, Good WV, Adams LC, Paradis H. Expression of tubedown- 1 is suppressed in retinal neovascularization of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2001;42:3000-3007.
11. Wall DS, Gendron RL, Good WV, et al. Conditional knockdown of Tubedown-1 in endothelial cells leads to neovascular retinopathy. Invest Ophthalmol Vis Sci. 2004;45:3704-3712.
12. Paradis H, Islam T, Tucker S, Tao L, Koubi S, Gendron RL. Tubedown associates with cortactin and controls retinal endothelial cell permeability to albumin. J Cell Sci. 2008;121:1965-1972.
13. Sugiura N, Adams SM, Corriveau RA. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J Biol Chem. 2003;278:40113-40120.
14. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem J. 2005; 386:433-443.
15. Paradis H, Liu CY, Saika S, et al. Tubedown-1 in TGF-b2 mediated remodeling of the developing vitreal vasculature in vivo and regulation of capillary outgrowth in vitro. Dev Biol. 2002;249:140-155.
16. Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR. Induction of apoptosis in human cells by RNAimediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene. 2006;25: 4350-4360.
17. Martin DT, Gendron RL, Jarzembowski JA, et al. Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors. Clin Cancer Res. 2007;13:1480-1487.
18. Willis DM, Loewy AP, Charlton-Kachigian N, Shao JS, Ornitz DM, Towler DA. Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex. J Biol Chem. 2002;277: 37280-37291.
19. Gautschi M, Just S, Mun A, et al. The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol Cell Biol. 2003;23:7403-7414.
20. Kimura Y, Saeki Y, Yokosawa H, Polevoda B, Sherman F, Hirano H. N-terminal modifications of the 19S regulatory particle subunits of the yeast proteasome. Arch Biochem Biophys. 2003;409:341-348.
21. Polevoda B, Sherman F. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J Mol Biol. 2003;325:595-622.
22. Geissenhoner A, Weise C, Ehrenhofer-Murray AE. Dependence of ORC silencing function on NatA-mediated N-alpha acetylation in Saccharomyces cerevisiae. Mol Cell Biol. 2004;24:10300-10312.
23. Wang X, Connelly JJ, Wang CL, Sternglanz R. Importance of the Sir3 N-terminus and its acetylation for yeast transcriptional silencing. Genetics. 2004;168:547-551.
24. Asaumi M, Iijima K, Sumioka A, et al. Interaction of N-terminal acetyltransferase with the cytoplasmic domain of beta-amyloid precursor protein and its effect on A beta secretion. J Biochem (Tokyo). 2005;137:147-155.
25. Lim JH, Park W, Chun YS. Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res. 2006;66:10677-10682.
26. Arnesen T, Van Damme P, Polevoda B, et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad Sci U S A. 2009;106:8157-8162.
27. Perrot M, Massoni A, Boucherie H. Sequence requirements for N-alpha-terminal acetylation of yeast proteins by NatA. Yeast. 2008;25:513-527.
28. Arnesen T, Betts MJ, Pendino F, et al. Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. BMC Biochem. 2006;7:13.
29. Gendron RL, Good WV, Miskiewicz E, Tucker S, Phelps DL, Paradis H. Tubedown-1 (Tbdn-1) suppression in oxygen-induced retinopathy and in retinopathy of prematurity. Mol Vis. 2006;12:108-116.
30. Infeld DA, O'Shea JG. Diabetic retinopathy. Postgrad Med J. 1998; 74:129-133.
31. Saika S, Saika S, Liu CY, et al. TGFβ2 in corneal morphogenesis during mouse embryonic development. Dev Biol. 2001;240:419-432.
32. Gendron RL, Liu CY, Paradis H, Adams LC, Kao WW. MK/T-1, an immortalized fibroblast cell line derived using cultures of mouse corneal stroma. Mol Vis. 2001;7:107-113.
33. Pino RM, Thouron CL. Vascular permeability in the rat eye to endogenous albumin and immunoglobulin G (IgG) examined by immunohistochemical methods. J Histochem Cytochem. 1983;31: 411-416.
34. Liao R, Gonzalez-Fernandez F. Albumin is not present in the murine interphotoreceptor matrix, or in that of transgenic mice lacking IRBP. Mol Vis. 2004;10:1038-1046.
35. Bairati A Jr, Orzalesi N. The ultrastructure of the pigment epithelium and of the photoreceptor pigment epithelium junction in the human retina. J Ultrastruct Res. 1963;9:484-498.
36. Zinn KM, Benjamin-Henkind J. Retinal pigment epithelium. In: Duane TD, ed. Biomedical Foundations of Ophthalmology. Philadelphia: Harper & Row; 1991:1-20.
37. Sumita R. Electron microscopic study of the choroid, I: the fine structure of Bruch's membrane (lamina vitrea) in the choroid. Acta Soc Ophthalmol Jpn. 1961;65:1188-1203.
38. Garron LK. The ultrastructure of the retinal pigment epithelium with observations on the choriocapillaris and Bruch's membrane. Trans Am Ophthalmol Soc. 1963;61:545-588.
39. Hornsby PJ. Senescence and life span. Pflugers Arch. 2010;459: 291-299.
40. Mishima K, Handa JT, Aotaki-Keen A, Lutty GA, Morse LS, Hjelmeland LM. Senescence-associated beta-galactosidase histochemistry for the primate eye. Invest Ophthalmol Vis Sci. 1999;40:1590-1593.
41. Green WR. Histopathology of age-related macular degeneration. Mol Vis. 1999;5:27-36.
42. Guymer RH, Bird AC, Hageman GS. Cytoarchitecture of choroidal capillary endothelial cells. Invest Ophthalmol Vis Sci. 2004;45: 1660-1666.
43. Hirabayashi Y, Fujimori O, Shimizu S. Bruch's membrane of the brachymorphic mouse. Med Electron Microsc. 2003;36:139-146.
44. Hadfield KD, Rock CF, Inkson CA, et al. HtrA1 inhibits mineral deposition by osteoblasts: requirement for the protease and PDZ domains. J Biol Chem. 2008;283:5928-5938.
45. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27:622-647.
46. Liang FQ, Godley BF. Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mech-anism for RPE aging and age-related macular degeneration. Exp Eye Res. 2003;76:397-403.
47. McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:4982-4991.
48. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006;86:279-367.
49. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol. 1999;97:217-228.
50. Liu H, Demetriades AM, Xiao WH, Campochiaro PA, Vinores SA. Mouse model of post-surgical breakdown of the blood-retinal barrier. Curr Eye Res. 2004;28:42142-42146.
51. Tomasek JJ, Haaksma CJ, Schwartz RJ, et al. Deletion of smooth muscle alpha-actin alters blood-retina barrier permeability and retinal function. Invest Ophthalmol Vis Sci. 2006;47:2693-2700.
52. Sander B, Thornit DN, Colmorn L, et al. Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest Ophthalmol Vis Sci. 2007;48:3983-3987.
53. de Bruin DM, Burnes DL, Loewenstein J, et al. In vivo threedimensional imaging of neovascular age-related macular degeneration using optical frequency domain imaging at 1050 nm. Invest Ophthalmol Vis Sci. 2008;49:4545-4552.
54. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11:109-119.
55. Leenders W, van Altena M, Lubsen N, Ruiter D, De Waal R. In vivo activities of mutants of vascular endothelial growth factor (VEGF) with differential in vitro activities. Int J Cancer. 2001;91:327-333.
56. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene. 2001;20:6418-6434.
57. Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J. 2004;382:13-25.
58. Kessels MM, Qualmann B. Extending the court for cortactin: from the cortex to the Golgi. Nat Cell Biol. 2005;7:448-449.
59. Kowalski JR, Egile C, Gil S, Snapper SB, Li R, Thomas SM. Cortactin regulates cell migration through activation of N-WASP. J Cell Sci. 2005;118:79-87.
60. Bake S, Friedman JA, Sohrabji F. Reproductive age-related changes in the blood brain barrier: expression of IgG and tight junction proteins. Microvasc Res. 2009;78:413-424.
61. Chrissobolis S, Faraci FM. The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends Mol Med. 2008;14:495-502.
62. Kortvely E, Hauck SM, Duetsch G, et al. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest Ophthalmol Vis Sci. 2010;51:79-88.